Further survival analysis showed that high MPZL1 expression was strongly associated with a poor prognosis in glioma patients (Fig. 1H; Fig. S3C–E; Kaplan Meier, P < 0.05). This evidence concerns the gene MPZL1 and central nervous system cancer.